8 assets in Hereditary Breast Ovarian Cancer Syndrome

Therapeutic assets addressing Hereditary Breast Ovarian Cancer Syndrome, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Olaparib Hereditary Breast Ovarian Cancer Syndrome	VA Office of Research and Development	P3	BB (70)
Carboplatin Hereditary Breast Ovarian Cancer Syndrome	VA Office of Research and Development	P2	BB (67)
Cis-Diamminedichloroplatinum Ii Hereditary Breast Ovarian Cancer Syndrome	University Health Network, Toronto	P2/3	BB (64)
Metformin Hereditary Breast Ovarian Cancer Syndrome	Alliance for Clinical Trials in Oncology	P3	B (60)
Deslorelin Hereditary Breast Ovarian Cancer Syndrome	City of Hope Medical Center	P2	CCC (53)
Testosterone Undecylate Hereditary Breast Ovarian Cancer Syndrome	City of Hope Medical Center	P2	CCC (53)
Capivasertib Hereditary Breast Ovarian Cancer Syndrome	M.D. Anderson Cancer Center	P1	CC (43)
Vistusertib Hereditary Breast Ovarian Cancer Syndrome	M.D. Anderson Cancer Center	P1	CC (43)